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Introduction
nxiety is a normal response to environmental
stressors, and promotes safety by facilitating behavioral
avoidance of threatening stimuli. This sense of threat is
modulated by fear circuitry, including amygdala, hip-
pocampus, and prefrontal regions. Anxiety disorders are
thought to involve alterations in fear responsivity, driven
by adjustments in the tuning of specific circuit compo-
nents, including deficiencies in the dampening of amyg-
dala stress responses by prefrontal regions.
1The neuronal
circuitry involved in the regulation of anxiety operates
within a context of environmental cues and across a
developmental landscape, such that assessment of nor-
mal developmental tasks and environmental stressors are
essential for clinical evaluation. The distress associated
with clinical anxiety often elicits intense escape urges,
offering immediate symptom relief. This avoidance is so
reinforcing that it may rapidly become habitual, resulting
in increasingly impaired functioning. Treatment requires
reducing reinforcements associated with avoidance while
gradually empowering youth to tolerate anxiety in the
face of potentially stressful challenges. 
Pharmacologic interventions may confer clinical benefit
by reducing the degree of anxious reactivity, thereby
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Anxiety disorders are the most common mental health
diagnoses in youth, and carry risks for ongoing impair-
ments and subsequent development of other psychiatric
comorbidities into adulthood. This article discusses con-
siderations for assessment and treatment of anxiety dis-
orders in youth, with a focus on the evidence base of
pharmacologic treatment and important clinical consid-
erations to optimize care. We then briefly describe the
impact of anxiety on neuronal elements of fear circuitry
to highlight how treatments may ameliorate impairments
through enhanced plasticity. Overall, pharmacotherapy
for anxiety disorders is effective in improving clinical symp-
toms, particularly in combination with psychotherapy.
Response is typically seen within several weeks, yet longi-
tudinal studies are limited. Selective serotonin reuptake
inhibitors are thought to be relatively safe and effective
for acute treatment of several classes of anxiety disorders
in youth, with increasing evidence supporting the role of
neuronal plasticity in recovery. 
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learn more adaptive responses to stressful stimuli. With
successful treatment, extinction of recurrent anxiety
symptoms is thought to require neuronal plasticity to
take effect, similar to other forms of learning. Selective
serotonin uptake inhibitors (SSRIs) and other treatment
modalities are thought to facilitate these neurochemical
and neuroanatomical enhancements, contributing to
clinical effectiveness.
2This enhanced neuroplasticity may
also contribute to better response rates by augmenting
other interventions such as psychotherapy. 
Assessment and diagnosis of anxiety
Initial identification of anxiety disorders in children and
adolescents often occurs during medical visits to primary
care providers. Presenting concerns typically include
avoidance of age-appropriate tasks, or excessive physical
complaints such as headaches, dizziness, or stomachaches,
which are particularly common presenting signs of anxi-
ety at younger ages.
3 Physical complaints related to anx-
iety can be diverse,
4 and are often highly concerning to
parents. A timeline of physical, psychological, and behav-
ioral symptoms, elicited from both the child and parents,
is valuable to assess the evolution of symptoms and con-
sider exacerbating factors. A broad review focused on the
association between symptoms and psychosocial stress is
also recommended, including past medical history and
family history of psychiatric illnesses and substance
abuse. General screening measures tailored to develop-
mental level are available for providers to help identify
children with psychosocial difficulties,
5 and self-reports
may help to identify anxiety in children who are disin-
clined to reveal symptoms during examination.
6
Medical evaluation
Despite the potential for physical symptoms to represent
somatic complaints driven by anxiety, consideration of
common medical issues related to anxiety disorders is
essential.
9,7 Physical examination and judicious labora-
tory testing targeting potential underlying relevant med-
ical problems should be performed.
8 Common screens
include tests for endocrine abnormalities (thyroid and
fasting glucose), urine toxicology, respiratory problems,
sleep abnormalities, cardiac conduction defects (partic-
ularly if considering tricyclic agents), and seizure activ-
ity. Pertinent findings can guide more specialized and
optimum management of symptoms, yet excessive test-
ing or otherwise providing reinforcement of symptom
emergence through heightened interventions is not rec-
ommended.
Treatment of anxiety disorders
A multimodal treatment approach, including a combi-
nation of medication, therapy, and environmental inter-
ventions, is increasingly shown to confer greater
improvement in symptoms compared with unimodal
treatments. Although the essential elements of success-
ful therapy are not clear, cognitive-behavioral therapy
(CBT) studies have extensively demonstrated effective-
ness in individual, group, and family formats.
9
Randomized controlled trials (RCTs) of CBT have
shown benefit for Generalized Anxiety Disorder
(GAD),
10-14 social anxiety disorder,
10-14 panic disorder,
13
obsessive–compulsive disorder (OCD),
14-16 and post-trau-
matic stress disorder (PTSD).
18These benefits have also
been found to be maintained over time.
19Therefore, for
youth who meet criteria for anxiety disorders with mild-
to-moderate functional impairments, the American
Academy of Child and Adolescent Psychiatry recom-
mends psychoeducation for patients and their families
and initially deferring use of medication to CBT.
20
However, for youth with moderate to severe anxiety
symptoms, multimodal treatment is recommended,
including medication in combination with CBT.
21
Multiple RCTs support the efficacy of SSRIs, both alone
and in combination with therapy, for the treatment of
anxiety disorders in children and adolescents.
Medication intervention may be started concurrently
with psychotherapy, or may be initiated before starting
therapy to reduce the impairing nature of severe symp-
toms and promote treatment effectiveness. Medication
can also be added after engagement in CBT if initial psy-
chotherapy does not provide satisfactory relief of symp-
toms. It is important to recognize that both psychother-
apy and medication management result in improvement,
but not necessarily in full remission of symptoms. 
When considering pharmacologic agents, selection
should be guided by the evidence base and clinical
guidelines, with special consideration for side-effect pro-
files and unique clinical characteristics to optimally tai-
lor care. Informed consent is required from parents, and
when possible, from the child or adolescent. States vary
in policies regarding obtaining consent or assent from
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ication use with the patient is likely to improve compli-
ance and engagement irrespective of age. 
When initiating medications, frequent visits with the pre-
scriber, typically every 2 to 4 weeks, are recommended
to closely monitor for effectiveness and tolerance.
Regular communication between the prescriber and the
treating therapist is also encouraged. More frequent
provider contact is also recommended when there is a
history of depression, a strong familial preference, or
when compliance is a concern. Standardized rating scales
should be used to measure treatment effectiveness. After
an effective dose of medication is reached, visit fre-
quency may be reduced. Even after symptom resolution,
cautious treatment calls for medication maintenance for
1 year, followed by a gradual tapering off to allow obser-
vation of any recurrence of symptoms.
22
Evidence for effectiveness of 
SSRIs and SNRIs
A limited number of RCTs have evaluated antianxiety
agents in children and adolescents. To date, no medica-
tions have been approved by the FDA for treatment of
non-OCD anxiety in youth. Four medications have been
approved for OCD treatment in children and adoles-
cents. Medication and placebo response rates range
across studies, which are difficult to compare due to lim-
ited clinical samples and variability in measures of
assessment and clinical response. Yet positive results
have been demonstrated for multiple agents in the treat-
ment of anxiety in both youth and adults, particularly
medications targeting serotonin reuptake. A meta-analy-
sis of RCTs examining the tolerability and efficacy of
pharmacotherapy for anxiety disorders in youth found
that SSRIs and SNRIs showed clear benefit with an
overall response rate almost double that of placebo.
23
Regarding specific pediatric anxiety subtypes, OCD has
the largest number of positive RCTs, which reveal clin-
ical benefit after treatment with sertraline,
15,24 fluoxe-
tine,
25,26 fluvoxamine,
27 or paroxetine.
28,29 Evidence for
citalopram is limited to open-label studies
30-32 and com-
parison with fluoxetine without placebo.
33 SSRIs are
first-line therapy for pharmacologic management of anx-
iety disorders in youth, and three of the four medications
approved by the FDA for treatment of OCD in children
and adolescents are SSRIs: sertraline (≥6), fluoxetine
(≥7), and fluvoxamine (≥8).
3
The highest regarded clinical trial examining the impact
of both manualized psychotherapy and medication on
symptoms of OCD in youth is the Pediatric OCD
Treatment Study (POTS). In this study, sertraline’s effec-
tiveness in pediatric OCD for 12 weeks was compared
with CBT, combined treatment, and placebo.
13 Each
active treatment arm proved superior to placebo, and
combined treatment was superior to either CBT or ser-
traline alone. Another RCT examining sertraline for
youth with OCD also found significantly greater
improvement after active treatment compared with
placebo,
24 with lasting effects in 70% of patients who
were examined 12 months later.
35
A 10-week RCT of pediatric outpatients with OCD
showed fluvoxamine to be effective.
27 Despite the com-
mon clinical finding that weeks of treatment with SSRIs
are required prior to symptom response, improvements
beyond placebo were evident by the first week and
showed gains through the course of treatment. 
Other SSRIs with RCTs demonstrating effectiveness in
the treatment of pediatric OCD include paroxetine
28,29
and fluoxetine.
25,26 Notably, fluoxetine treatment required
8 weeks prior to showing effectiveness over placebo, and
a higher dose only lengthened this response time.
Secondary analyses also showed that paroxetine demon-
strated significantly lower response rates among youth
with OCD and comorbid illness such as ADHD, tic dis-
orders, or oppositional defiant disorder (ODD).
29
Overall, these clinical studies suggest a moderate treat-
ment effect that is relatively similar across SSRIs.
23
Despite the much greater prevalence of non-OCD anx-
iety disorders, studies are more limited in children and
adolescents. Furthermore, subtypes are often mixed
within treatment arms, limiting the ability to compare
response to treatment by specific disorder. Nevertheless,
RCTs of SSRIs have demonstrated efficacy in the treat-
ment of GAD, separation anxiety disorder (SAD), and
social phobia, often in mixed populations with any one
or a combination of these (Table I). Although the data
are limited, the average likelihood of pharmacologic
treatment response for non-OCD disorders appears to
be slightly greater than for OCD.
23
The largest RCT of non-OCD anxiety disorders to date
is the Childhood Anxiety Multimodal Study (CAMS),
which evaluated treatment of SAD, GAD, and social
phobia.
36Treatment groups included sertraline only, CBT
only,
37 combination treatment, or placebo. All three
active treatments were superior to placebo (24%), with
Pharmacotherapy for childhood anxiety disorders - Kodish et al Dialogues in Clinical Neuroscience - Vol 13 . No. 4 . 2011
441
PAGES_12_AG_1005_BA.qxd:DCNS#51  1/12/11  14:54  Page 441the highest response in the combined condition. These
findings again suggest that, while monotherapy with
either medication or psychotherapy alone can be effec-
tive for treating anxiety disorders, a multimodal
approach is more likely to be successful. This method is
also thought to apply to pediatric depression
38 and com-
plex forms of ADHD,
39 while evidence for combination
therapy is limited for youth with PTSD.
40,41
Other agents with demonstrated efficacy for youth with
non-OCD anxiety include fluvoxamine
42,43 and fluoxe-
tine.
44 An open-label follow-up study showed that 94%
of the fluvoxamine responders exhibited a sustained
benefit after 6 months.
44 Furthermore, nonresponders to
initial fluvoxamine treatment still exhibited a high rate
of response to a subsequent open-label trial of fluoxe-
tine, supporting the clinical benefit of a subsequent trial
using alternative SSRIs despite an initial lack of
response to one agent. 
Fewer studies have examined selective cohorts with
diagnoses of specific non-OCD anxiety disorders. An
RCT examining paroxetine treatment in youth specifi-
cally with social anxiety showed efficacy over placebo.
35
In addition, a small RCT of youth with GAD found a
robust response to sertraline after 9 weeks, in contrast to
a low placebo response.
45 RCTs of medication response
in youth with PTSD indicate limited improvement in
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RCT Medication Length Dosing Total Ages and Effect size of Number  Clinical Notable 
Author (weeks) (mean) N diagnoses treatment needed outcome/ side effects
to treat response rate
RUPP Anxiety  Fluvoxamine  8 Fixed-flexible. 128 6–17 1.1 2 CGI-I ≤ 2 Abdominal
Study Group,  (FLV) (4.0 mg/kg/day) GAD, SoP, SAD FLV 76% discomfort,
2001
43 PBO 29% ↑ Activity
Rynn, Siqueland, Sertraline (SER) 9 Fixed. 22 5–17 1.9 1 CGI–I ≤ 2
& Rickels, 2001
46 (50 mg) GAD SER 90%
PBO 10%
Birmaher et al,  Fluoxetine (FLX) 12 Fixed. 74 7–17 0.4 4 CGI-I ≤ 2 Abdominal
2003
45 (20 mg) GAD, SoP, SAD FLX 61% pain,
PBO 35% agitation
Wagner et al,  Paroxetine (PAR) 16 Flexible. 322 8–17 N/A 3 CGI-I ≤ 2 Insomnia,
2004
36 10–50 mg/day SoP PAR 78% ↓ Appetite,
(24.8 mg) PBO 38% vomiting, 
agitation
Black & Uhde,  Fluoxetine (FLX) 12 Fixed. 15 6–11 0.67 N/A CGI-I ≤ 3
1994
133 (0.6 mg/kg/day) Elective mutism FLX 80%
PBO 40%
Walkup et al, Sertraline (SERT) 12 Fixed-flexible. 488 7-17 COMB=0.86 COMB=1.7 CGI-I ≤ 2 Insomnia,
2008
37 COMB (133.7 mg) GAD, SoP, SAD SERT=0.45 SERT=3.2 COMB=80.7% fatigue,
SERT (146.0 mg) CBT=0.31 CBT=2.8 SERT=54.9% restlessness
CBT=59.7%
PBO=23.7
March et al, Venlafaxine ER 16 Weight-based 293 8-17 0.46 5 CGI-I ≤ 2 Anorexia,
2007
50 (VFX) flexible. SoP VFX=56% asthenia,
(141.5mg) PBO=37% nausea
Rynn et al, Venlafaxine ER 8 Weight-based, 320 6-17 0.42 N/A CGI-I ≤ 2 Headache,
2007
49 (VFX) flexible. GAD VFX=69% abdominal
(pooled studies) PBO=48% pain,
anorexia
Table I. Randomized controlled trials of SSRIs and SNRIs in pediatric non-OCD anxiety disorders. CGI–I: Clinical Global Impressions-Improvement Scale;
COMB: combined; CBT: cognitive-behavioral therapy
PAGES_12_AG_1005_BA.qxd:DCNS#51  1/12/11  14:54  Page 442symptoms with the addition of sertraline to trauma-
focused CBT,
40 and lack of efficacy compared with
placebo after 10 weeks.
41 Some studies have shown ben-
efit from SSRIs,
47 yet trauma-focused CBT has shown
more consistent effectiveness.
47 To date, no RCTs have
examined medication effects in children or adolescents
with panic disorder.
Aside from SSRIs, medications with dual inhibiting
actions on serotonin and norepinephrine (SNRIs) have
also been tested in youth with anxiety disorders.
Specifically, venlafaxine XR was examined in two 8-
week RCTs in children with GAD. Despite insignificant
improvement on a primary measure in one of the trials,
pooled results revealed significantly greater response in
the active medication group compared with placebo.
48
Another 16-week RCT of venlafaxine XR in children
with social anxiety showed significant benefit beyond
placebo.
49 However, studies of venlafaxine in children
indicated a risk for elevated blood pressure, decreased
growth rate, and increased suicidal ideation, which
should be considered with families prior to initiating
treatment. A meta-analysis of RCTs examining the tol-
erability and efficacy of pharmacotherapy for anxiety
disorders found that SSRIs and SNRIs showed clear
benefit with an overall response rate almost double that
of placebo treatment, with SSRIs slightly more benefi-
cial than venlafaxine XR.
23
Due to the lack of comparative head-to-head RCTs of
SSRIs or SNRIs, choice of agent is often based on side-
effect profiles, interactions with other medications, and
family history of medication response. Furthermore, only
short-term benefits have been evaluated in RCTs, and
research findings may not generalize to clinic popula-
tions due to exclusion of youth with medical or psychi-
atric comorbidities. 
Age may also be an important consideration in phar-
macotherapy. Despite age-related differences in metab-
olism and observations that SSRIs may be more effec-
tive in the treatment of adolescent depression compared
with depressed younger children, findings from RCTs in
anxious youth do not show differential effects based on
age.
23,50The evidence base is particularly limited for phar-
macologic treatment of anxiety in children under the age
of 6.
51 Given the limited pharmacologic data, CBT, tai-
lored to developmental level, is considered to be the first
line treatment in children this young. In cases with high
acuity unresponsive to psychotherapy, medication treat-
ment may be considered.
Safety concerns with SSRIs and SNRIs
Heightened concern for the negative effects of SSRIs
and SNRIs in youth, particularly for activation and
emerging suicidality, have impacted familial willingness
and clinical practice to initiate treatment with these
agents, particularly for children with anxiety.
52 Clinical
practice suggests that children with anxiety tend to be
more sensitive to potential side effects of these medica-
tions, particularly physical discomfort. Lower starting
doses should be considered to mitigate these effects.
Other common side effects include nausea, headaches,
sleep abnormalities, and sexual side effects of reduced
libido and physical responsiveness. Dropouts in RCTs as
a result of adverse events from SSRIs and SNRIs were
almost twice as common among subjects taking active
medication compared with placebo.
24 Side effects tend
to emerge earlier in the course of treatment or during
dosage adjustments, and may subside over days to weeks. 
Importantly, antidepressants carry a black-box warning
from the FDA out of concern that they may potentiate
suicidal thinking, a low-frequency event that neverthe-
less warrants prior consent
53 and the development of a
monitoring strategy. Suicidal thoughts may be related to
the activating effects of SSRIs, resulting in heightened
somatic experiences of anxiety, increased emotional
lability, and impulsivity. Results from a RCT examining
activation as a side effect of fluvoxamine in anxious
youth indicated heightened risk of activation through-
out the course of titration.
54
Despite their relative safety and tolerance, abrupt dis-
continuation of shorter-acting agents often results in
generalized discomfort and flu-like symptoms.
Medications often require 4 to 8 weeks to provide clini-
cal benefit, and potentially longer when starting with low
doses. Educating families about these expectations and
concerns often prevents them from abandoning med-
ication trials prematurely.
Tricyclic antidepressants
Tricyclic antidepressants (TCAs) have also shown effi-
cacy in several RCTs of youth with anxiety, particularly
clomipramine, which carries an FDA indication for treat-
ment of OCD in children aged 10 and over. RCTs exam-
ining treatment of social anxiety or school refusal have
shown benefits of both imipramine
55-57 and
clomipramine.
58,59Although TCAs may be considered for
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as augmentation to SSRIs for partial response in youth
with OCD.
60TCAs are generally less preferred because
they require EKG monitoring due to the potential for
cardiac abnormalities, carry high risk of fatality in over-
dose, and have constipation and sedation as side effects. 
Other agents
Controlled trials do not support the use of benzodi-
azepines in children
61,62 yet open-label studies indicate
symptomatic benefit,
63 and multiple agents in this category
are used in clinical practice for highly anxious children.
Prior to initiating treatment, it is important to discuss
management issues, the potential for tolerance, risk of
seizure from abrupt discontinuation, and that short-term
rather than long-term use is preferred due to addiction
potential. Benzodiazepines can also cause cognitive blunt-
ing or disinhibition in some children, leading to behavioral
agitation. Nonetheless, when children have severe symp-
toms unresponsive to other treatments, benzodiazepine
use early in treatment can help to reduce symptoms and
promote participation in therapy or school attendance,
particularly before SSRIs become effective. No long-term
studies are available for use in children, but benzodiaza-
pines are noted to have potential for psychological and
physical dependence in adults.
64
Several other agents have been used in clinical practice,
but have more limited support in the literature.
Buspirone, a partial agonist of serotonin receptors,
demonstrated effectiveness at 2 weeks with no adverse
effects compared with placebo in a small placebo-con-
trolled study with mixed anxiety disorders.
65
Central α-agonists, guanfacine and clonidine, have been
considered in treatment of youth with PTSD and dysreg-
ulated behavior.
66 However, controlled research support-
ing the use of these agents is lacking. A small open-label
study of clonidine in patients aged 3 to 6 with PTSD was
shown to decrease arousal, aggression, and anxiety.
67
Mirtazapine is an antidepressant with some evidence of
efficacy for treating anxiety in adults.
68 Evidence in youth
is limited, with one positive open-label study for social
phobia.
69This agent may be a consideration to capitalize
on its sedating and appetite-stimulating properties for
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Table II. Treatment algorithm for pediatric anxiety pharmacotherapy. 
aIn June 2003, the FDA recommended against the use of paroxetine for Major
Depressive Disorder in children and adolescents. EKG, electrocardiogram; BP, blood pressure; 5-HTa PA, serotonin partial agonist; Rx,  prescribe;
HTN, hypertension; OCD, obsessive-compulsive disorder; SSRI, selective serotonin reuptake inhibitor; GAD, generalized anxiety disorder
Treatment
algorithm
Class
Medication
Starting dose
Total therapeutic
dose range
Common side-effect
profile
Special warning/
monitoring
Specific indications
FDA approval
Sertraline
12.5-25 mg
50-200 mg
Nausea,
sedation,
headache
GAD
For OCD; 
≥ 6
Fluoxetine
5-10 mg
10-60 mg
Activation,
nausea,
insomnia
Long half-life
For OCD; 
≥ 7
Fluvoxamine
12.5-25 mg
50-200 mg 
(Rx bid above 50 mg)
Hyperactivity, 
abdominal discomfort
For OCD; 
≥ 8
Citalopram
5-10 mg
10-40 mg
Somnolence,
insomnia,
diaphoresis
No RCTs;
little interactions
For adults 
Paroxetine
a
5–10 mg
10-40 mg
Sedation,
nausea,
dry mouth
Social phobia; 
non-depressed
For adults 
→
→
→
Suicidality, activation (restlessness, impulsivity), Serotonin Syndrome; 
Develop safety plan and means to assess early side effects, which may resolve in 1-2 weeks; 
avoid abrupt discontinuation with paroxetine, 
sertraline, fluvoxamine, and citalopram.
Select SSRI. Titrate up every 2-4 weeks until symptoms respond, 
until side effects preclude further dose increases, 
or when reach max dose.  If ineffective or intolerable, use alternate SSRI for 2nd trial.
SSRI
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sponsive to SSRIs. 
Propranolol is another agent with some evidence of
effectiveness in adults, but lacks systematic data to sup-
port its use in children and adolescents. A crossover pilot
study of propranolol in 11 pediatric patients with PTSD
also showed improvements relative to placebo in treat-
ing symptoms of hyperarousal and intrusivity in the
majority of patients.
70
There are also a variety of other agents that are occa-
sionally used despite the lack of controlled evidence. For
example, buproprion, an inhibitor of dopamine and nor-
epinephrine, has not been studied in children or adoles-
cents with anxiety. Similarly, gabapentin has limited evi-
dence of improvement in anxiety symptoms in adults,
71,72
but has not been tested in youth. 
Another intriguing possibility is D-cycloserine, a partial
agonist at the N-methyl-D-aspartate receptor that is
thought to potentiate gains from exposure therapy. Two
RCTs have supported its use as an augmentation strat-
egy for youth with OCD
73 and social anxiety disorder.
74
While D-cycloserine does not have direct benefits in the
absence of other treatments, it is thought to increase the
efficacy of psychotherapy by facilitating mechanisms of
neuroplasticity.
75
Complementary and alternative remedies are often tried
by families prior to seeking psychiatric treatment. One
study found that “anxiety and stress” was the third most
common reason for the use of complementary and alter-
native medicines in children and adolescents.
76-77 While
rigorous evidence is lacking to support the use of natur-
opathic medications, the plant Kava has some evidence
of effectiveness in multiple treatment trials.
78 In addition,
a review of medicinal plants for the treatment of anxiety
disorder found that ginkgo biloba and matricaria recu-
tita showed effect sizes similar to those in studies of anti-
depressants and benzodiazapines.
79
Overall, the use of SSRIs remains the first-line treat-
ment, with the best evidence-base. However, for the
patients who can not tolerate or do not benefit from
SSRIs, a variety of other treatment options can be con-
sidered. A proposed treatment algorithm is described in
Table II, and is expected to need refinement as clinical
evidence grows.
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Table II. Continued
5-HTa PA
Buspirone
5 mg tid
1–60 mg
(Rx tid)
Sedation,
disinhibition,
headache
Safe with 
benzodiazepines
Augmentation;
sexual side effects
For adults
Tetracyclic
Mirtazapine
7.5-15 mg
7.5–30 mg
(Rx qhs)
Hunger,
sedation,
dizziness
Weight gain
Appetite stimulation,
insomnia; 
few interactions
For adults
→
→
→
→
→
→
Clonazepam
0.25-0.5 mg
0.25–  mg
(Rx qd-tid)
Sedation, 
confusion
Disinhibition, 
tolerance, 
seizure from 
discontinuation
Short-term relief
of acute anxiety; 
longer acting
For adults
Lorazepam
0.5-1 mg
0.5– 6 mg
(Rx qd-qid)
Sedation,
confusion
Disinhibition, 
tolerance, seizure from
discontinuation
Short-term relief of
acute anxiety; shorter
acting; liver impaired
For adults
If still no response, or familial prefer-
ence, consider buspirone or mirtazepine, 
alone or as augmentation.
Consider benzodiazepines for acute relief 
of severe symptoms or after no response 
to multiple trials.
Benzodiazepine Tricyclic
Clomipramine
25 mg
100–150 mg
Dry mouth,
constipation,
diaphoresis
Hypotension,
rebound HTN, 
lethal in OD; 
level ≤400
OCD; EKG, BP.
Monitoring to mini-
mize overdose risk
For OCD; 
≥ 10
SNRI
Venlafaxine XR (VFX)
37.5 mg
75–225 mg
(Rx qhs or bid)
Nausea,
sedation,
dizziness
HTN, tachycardia,
suicidality
GAD;
Non-depressed
For adults
After 2 failed SSRI trials, reassess or consult,
consider clomipramine for OCD; 
VFX for non-OCD.
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informed by diagnosis
Youth diagnosed with one anxiety disorder are quite likely
to have multiple anxiety disorders concurrently, including
Major Depressive Disorder, Attention Deficit-Hyperactivity
Disorder (ADHD), Oppositional Defiant Disorder (ODD)
and Tourette’s Disorder.
36,80 In CAMS, among youth who met
criteria for one or more anxiety disorders, 46% met criteria
for other internalizing disorders, 11.9% for ADHD, 9.4% for
ODD, and 2.7% for tic disorders.
36 Providers should there-
fore broadly evaluate anxiety symptoms, and assess the
degree of impairment thought to be driven by subtypes in
order to prioritize treatment. Attention to these comorbidi-
ties is essential for comprehensive treatment but may require
a stepwise approach. 
Risk factors for having a combination of depression and
anxiety include older age and greater severity of anxiety
symptoms.
80 Although most RCTs of anxiety exclude
depressive disorder diagnosis from entry, open-label use
of citalopram showed a significantly lower rate of
response in patients with comorbid anxiety and depres-
sion versus either alone.
32
Children with behavioral dysregulation as a result of
anxiety may consequently display features of opposi-
tionality, leading to diagnoses of disruptive behavior dis-
order or ODD. Anxious children may intently refuse to
comply with demands of authority figures, such as leav-
ing the house on time or reading aloud in class, and
refrain from communicating the intense and often
embarrassing fear that drives this oppositionality. Family
psychoeducation and school coordination may thus
reduce conflict. Following treatment, features of exter-
nalizing disorders should be re-evaluated. 
Anxiety disorders in children also often co-occur with
ADHD.
81 Anxious children may have difficulty paying
attention because of hypervigilance or preoccupation
with peer concerns, as opposed to ADHD-related impair-
ments. Careful assessment is therefore essential to
address the core symptomatology, and also to monitor for
potential anxiogenic effects of medications during stim-
ulant trials. Children with ADHD and comorbid anxiety
who continued to exhibit anxious features following stim-
ulant treatment did not exhibit any further anxiety ben-
efit from the addition of fluvoxamine to their stimulant
regimen when compared with adding a placebo,
82 indi-
cating that polypharmacy should not be assumed to con-
fer improved efficacy in comorbid disorders. 
The majority of adolescents with substance abuse disor-
ders have comorbid psychiatric diagnoses, especially
anxiety.
83,84 Substance use increases risk for traumatic
events and often interferes with appropriate detection
and treatment of anxiety disorders.
85
Anxiety disorders also pose greater risk for developing
eating disorders, including anorexia nervosa,
86 and binge
eating.
87 Patients may vigilantly attend to food limits to
address their anxiety around eating and its conse-
quences, while nutritional benefits often impair brain
function and judgment. Fear of eating may further result
in extreme avoidance to psychotherapy. There is mini-
mal evidence supporting the use of SSRIs to aid weight
restoration,
88 yet pharmacologic management may nev-
ertheless be helpful to address co-occurring anxiety or
depression. 
Children with Autism Spectrum Disorders (ASDs) often
exhibit agitation and anxious responses to many stimuli,
including ritualistic and obsessive behaviors.
89The most
common comorbid diagnosis with ASDs is social anxi-
ety disorder.
90 One meta-analysis of the limited data on
treatment of children with ASDs found that SSRI treat-
ment was associated with reduced anxiety, decreased
repetitive behaviors, and improved global function.
91
However, two recent autism studies using citalopram
and fluoxetine for ritualistic behaviors were negative,
and another meta-analysis raised concerns for lack of
efficacy and risk of side effects when compared with
placebo groups.
92,93 Clinical recommendations neverthe-
less include consideration of SSRI use with symptoms of
anxiety in some children and adolescents with autism
spectrum disorder.
94
Although trichotillomania, or impulsive repetitive hair-
pulling, is listed as an impulse control disorder, the trig-
gers for repetitive hair-pulling are often anxious
thoughts,
95 and urges to pull are typically accompanied by
anxiety.
95,96 However, treatment studies using SSRIs have
shown low response rates.
97,98 CBT with “habit reversal
therapy” is the recommended first-line treatment.
99While
co-occurrence of the motor impairments of Tourette’s
Disorder with OCD is very common, treatment of one
disorder is not thought to significantly impact the symp-
tomatic impairments related to the other.
100
In contrast to pharmacotherapy for anxiety disorders in
youth, there are many more FDA approved-medications
for the treatment of anxiety in adults. These include mul-
tiple benzodiazepindes (alprazolam, clomipramine, clo-
razepate, lorazepam, oxazepam); multiple SSRIs (parox-
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SNRIs (venlafaxine); tricyclics (amitriptyline), MAO
inhibitors (phenelzine), and miscellaneous agents (bus-
pirone and hydroxyzine). These findings do not neces-
sarily support use in youth.
Neuroscience perspectives on anxiety 
disorders and treatments
As described elsewhere in this issue, anxiety disorders in
children and adults involve alterations in fear respon-
sivity, driven by adjustments in the tuning of specific
components of fear circuitry.
101,102 Excessive fear
responses are further thought to induce lasting structural
changes in several components of synaptic connectivity
and plasticity, contributing to the maintenance of anxi-
ety symptomatology, even when stressors are strictly
avoided.
103 Increasing understanding of anxiety treat-
ments, including both pharmacotherapy and CBT,
reveals that beyond avoiding stressors or simply forget-
ting past associations, alleviating the negative impact of
experiences requires active learning mechanisms,
thought to reorganize brain structure and function.
Behavioral improvements in animal models of anxiety
are thus prevented when these plasticity mechanisms are
experimentally inhibited.
104 Successful treatments likely
facilitate further neuronal adaptation to meet the
demands of appropriately responding to stressful stim-
uli. Improvements in the understanding of neural cir-
cuitry related to this adaptive resilience, in addition to
understanding the processes that catalyze change in
these circuits, allows for emerging neuronal targets to
enhance treatment. 
Multiple types of learning are known to induce struc-
tural adaptation in brain connectivity and function, and
this response is tailored to meet the demands of the spe-
cific learning tasks; while the aerobic demands of tread-
mill activity induce greater blood vessel growth in rat
cerebellar cortex, the increased learning demands of
acrobat training are associated with growth of synaptic
connectivity, termed synaptogenesis.
105 Stress can induce
emotional learning and similarly cause a specific pat-
terns of alterations in synaptic architecture. Evidence
from human childhood trauma studies suggest these
alterations may become maladaptive in extreme stress,
resulting in future volumetric reductions in hippocam-
pal regions when associated with subsequent PTSD.
106
Rodent models of chronic restraint stress (CRS) from
repeated confinement results in behavioral changes sug-
gestive of anxiety and depression. Neuroatanomic
changes include significant decreases in prefrontal and
hippocampal neuron dendrites, including reduced length,
branching, and postsynaptic spine number.
107 This mor-
phologic plasticity may initially be an adaptive response
to potential cytotoxicity, limiting vulnerability from
exposed excitatory receptors,
108 but when excessive,
eventually leads to impairments in structural plastic-
ity.
109,110 Despite the known adverse effects of severe
stress on neuronal circuitry and plasticity,
111 some stress-
ful experiences may actually confer future resilience,
particularly under later high stress conditions.
112,113
Similar to synaptogenesis and dendritic remodeling, neu-
rogenesis is understood as a lifelong adaptive brain
response which may be impacted by anxiety and its treat-
ments. Neurogenesis is upregulated by experiential fac-
tors such as enriched experience, while decreased in
many animal paradigms of stress and depression.
114
Similarly, the expression of neurotrophins and their
receptors, thought to underlie rapid changes in dendritic
and synaptic architecture, is impaired by stress and
enhanced under many learning conditions.
115 Interference
with neurogenesis or neurotrophic factor production in
the hippocampus prevents the behavioral effects of anti-
depressants to improve fearful responses in experimen-
tal animals.
116 Medications and CBT may therefore ame-
liorate maladaptive structural and neurochemical
responses by increasing the resilience of stress circuitry
to impairments in neuronal and synaptic proliferation,
thus allowing greater synaptic connectivity, adaptability,
and preserved function.
107
This notion is supported by experimental findings of
SSRI-induced trophic changes in several neuronal ele-
ments, including promoting neurotrophin expression and
neurogenesis in brain regions relevant to anxiety disor-
ders.
117 SSRIs have been shown to block the impairing
effect of stress on hippocampal neurogenesis and induce
both improved behavioral responses and elevations in
multiple synaptic remodeling proteins.
118 Furthermore,
chronic, but not acute, administration of SSRIs increase
the expression of neurotrophic factors,
115 suggesting that
the delay in clinical response to SSRIs may reflect the
time course of neurogenesis or other changes in neu-
ronal excitability.
11
Several other antianxiety medications, including SNRIs,
have been found to normalize behavior, and also restore
neurotrophin levels, in experimental animals. After
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restoration of neurotrophin levels and hippocampal neu-
rogenesis.
120 Duloxetine was also shown to increase local
neurotrophin transcription at synapses, enhancing plas-
ticity, and this effect was only seen after chronic admin-
istration.
121
Several of the mediators known to affect anxiety respon-
sivity, including both stressful experiences and thera-
peutic medications, are further thought to operate
through epigenetic mechanisms involving changes in the
regulation of chromatin arrangements by histone pro-
teins.
122,123 Similar neurotrophic effects in animals, medi-
ated by histone acetylation, are seen following environ-
mental enrichment treatments, with improved plasticity
and learning, even in mice with history of severe stress
or neurodegeneration.
124-126
As neurogenesis is limited to circumscribed brain regions
after early brain development, and SSRIs have been
shown to induce synaptic remodeling and behavioral
improvements even when neurogenesis is prevented,
127 it
is unlikely that one plasticity mechanism is solely respon-
sible for the improvements related to pharmacotherapy
for anxiety and mood disorders. Indeed, aside from
changes in synaptic architecture, neurochemical, physio-
logic, hormonal, and molecular mediators are also
thought to play essential roles in the response to stress
and its treatments.
128 Furthermore, while neuronal plas-
ticity and dendritic enhancements allow for change and
implementation of more adaptive neuronal networks,
they may also confer risk to greater consolidation of mal-
adaptive responses,
129 as proliferation is not strictly adap-
tive. In fact, dendritic proliferation is selectively increased
in some amygdala and orbitofrontal neurons in response
to stress, and is thought to contribute to impaired reac-
tivity.
130,131
These findings broadly indicate that anxiety treatments
should not exclusively target neurotransmitter deficits
but should focus on facilitating more adaptive neuronal
reorganization by enhancing the mechanisms of plastic-
ity thought to be impaired as a consequence of patho-
logic anxiety.
115 Multiple forms of treatment may work
synergistically to enhance this adaptive response. Future
pharmacologic agents might allow for greater precision
in targeting specific neuronal elements thought to mod-
ulate this process, particularly those affected in various
forms of psychiatric illness. 
Conclusion
Anxiety disorders are common in children and adoles-
cents, and contribute to significant impairments in qual-
ity of life, often stemming from behavioral avoidance that
may limit normative developmental tasks. While there
are many more RCTs of pharmacologic treatment of
anxiety disorders in adults as compared with youth, there
is increasing evidence that carefully implemented inter-
vention with medications improves symptoms in children
and adolescents, particularly when high acuity is present.
Best practice is for a combination approach of CBT
which adheres to manualized models, coupled with med-
ications. SSRIs are the agents of first choice for anxiety
disorders, with subsequent switch to an alternative SSRI
if a first trial is not successful. Other medication options,
including use of tricyclic antidepressants and short-term
use of benzodiazepines, may be considered, but lack the
evidence base and carry additional risks.
Emerging evidence from animal and human studies sug-
gests that anxiety disorders are associated with changes
in neuronal structure and function, and that effective
treatments with psychotherapy or medications refine
these abnormalities in a number of ways. Future treat-
ments may focus on enhancing this process to allow
emotional learning to facilitate resilience, as opposed to
contributing to maladaptive stress reactivity.  ❏
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Farmacoterapia de los trastornos ansiosos
en niños y adolescentes
Los trastornos ansiosos son los diagnósticos más
comunes de salud mental en los jóvenes y conllevan
riesgos de permanente deterioro y posterior desa-
rrollo de otras comorbilidades en la adultez. En este
artículo se discuten los aspectos a tener en cuenta
para la evaluación y tratamiento de los trastornos
ansiosos en la juventud focalizándose en los fun-
damentos para la evidencia del tratamiento farma-
cológico y en importantes consideraciones clínicas
para optimizar el manejo. Además se describe bre-
vemente el impacto de la ansiedad en los elemen-
tos neurales del circuito del miedo y se destaca
cómo los tratamientos pueden disminuir los dete-
rioros al mejorar la plasticidad. En general la far-
macoterapia de los trastornos ansiosos es efectiva
en la mejoría de los síntomas clínicos, especialmente
en combinación con la psicoterapia. Típicamente la
respuesta se observa en algunas semanas, aunque
los estudios longitudinales son limitados. Se cree
que los inhibidores selectivos de la recaptura de
serotonina son relativamente seguros y efectivos
para el tratamiento agudo de diversas clases de
trastornos ansiosos en la juventud, y hay evidencias
crecientes que dan sustento al papel de la plastici-
dad neuronal en la recuperación. 
Pharmacothérapie des troubles anxieux chez
les enfants et les adolescents
Le diagnostic des troubles anxieux est le diagnostic
de santé mentale le plus courant chez les jeunes ; il
comporte des risques de détériorations perma-
nentes et de développement ultérieur d’autres
comorbidités psychiatriques à l’âge adulte. Cet
article analyse les critères d’évaluation et de traite-
ment des troubles anxieux chez les jeunes, et il
insiste sur la pertinence du traitement pharmaco-
logique et sur certains aspects cliniques importants
pour optimiser les soins. Nous décrivons ensuite
brièvement l’impact de l’anxiété sur les éléments
neuronaux du circuit de la peur pour souligner
comment les traitements peuvent améliorer les
troubles par une augmentation de la plasticité. De
manière générale, le traitement pharmacologique
des troubles anxieux améliore les symptômes cli-
niques, en particulier en association avec une psy-
chothérapie. La réponse intervient généralement
sous plusieurs semaines, mais les études longitudi-
nales restent encore limitées. Les inhibiteurs sélec-
tifs de la recapture de la sérotonine sont relative-
ment sûrs et efficaces pour le traitement aigu de
plusieurs types de troubles anxieux chez les jeunes,
avec de plus en plus d’arguments en faveur du rôle
de la plasticité neuronale dans la guérison.
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